{"id":2062,"date":"2017-03-27T10:32:16","date_gmt":"2017-03-27T14:32:16","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=2062"},"modified":"2017-03-27T10:52:40","modified_gmt":"2017-03-27T14:52:40","slug":"april-ipo-calendar-begins-to-fill-up","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/april-ipo-calendar-begins-to-fill-up\/","title":{"rendered":"April IPO calendar begins to fill up"},"content":{"rendered":"<h3><a href=\"https:\/\/www.ipoboutique.com\/newsletter.htm\" target=\"_blank\">SUBSCRIBE TO IPOBoutique\u2019s Free Weekly Newsletter\u00a0<\/a><\/h3>\n<hr \/>\n<p>The April calendar is beginning to fall into place.<\/p>\n<p>After zero IPOs were on the schedule for this current week, our sources indicated that the first week of April would drum up more\u00a0activity. We heard of a few technology companies planning on launching an offering (<strong>Okta, Inc.<\/strong> did on Monday), but it was a nice surprise to see <strong>Hess Midstream\u00a0<\/strong>and\u00a0<strong>Elevate Credit<\/strong>\u00a0bring terms.<\/p>\n<p>Additionally, a late-stage biopharm, <strong>Akcea Therapeutics<\/strong>, filed for its IPO and it could be a candidate to go public in the first half of 2016.\u00a0When it comes to healthcare offerings, two of five in the sector have failed to come to market after launching and marketing its deal. Of the three biotech names that have gone public, one is trading well-below its offering price (ObsEva Inc.) and two have been some of the higher performers year-to-date (AnaptysBio &amp; Jounce Therapeutics).<\/p>\n<p>Below is the activity from the official filings on Monday morning with included trade dates.<\/p>\n<p><span style=\"text-decoration: underline;\"><strong>NEW FILINGS<\/strong><\/span><\/p>\n<p>Company: <strong>Akcea Therapeutics<\/strong><br \/>\nSymbol: AKCA<br \/>\nPrice: TBD<br \/>\nDescription: They are a late-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders.<br \/>\nTrade Date: TBD<br \/>\nShares: TBD<br \/>\nUnderwriter(s): Cowen and Company, Stifel, Wells Fargo Securities<br \/>\nFiled: 3-27-17<br \/>\nListed Cash Raise: $100m<\/p>\n<p><span style=\"text-decoration: underline;\"><strong>TERMS ADDED<\/strong><\/span><\/p>\n<p>Company: <strong>Elevate Credit<\/strong><br \/>\nSymbol: ELVT<br \/>\nPrice: $12.00-$14.00<br \/>\nDescription: They provide technology-driven, progressive online credit solutions to non-prime consumers, typically defined as those with credit scores of less than 700.<br \/>\nTrade Date: 4\/6<br \/>\nShares: 7.7 million<br \/>\nUnderwriter(s): UBS Investment Bank, Credit Suisse, Jefferies, Stifel, William Blair<br \/>\nTerms Added: 3-24-17<\/p>\n<p>Company: <strong>Okta, Inc<\/strong><br \/>\nSymbol: OKTA<br \/>\nPrice: $13.00-$15.00<br \/>\nDescription: They are the leading independent provider of identity for the enterprise.<br \/>\nTrade Date: 4\/7<br \/>\nShares: 11 million<br \/>\nUnderwriter(s): Goldman Sachs &amp; Co., J.P. Morgan, Allen &amp; Company<br \/>\nCo Manager(s): Pacific Crest Securities, Canaccord Genuity, JMP Securities<br \/>\nTerms Added: 3-27-17<\/p>\n<p>Company: <strong>Hess Midstream Partners LP<\/strong><br \/>\nSymbol: HESM<br \/>\nPrice: $19.00-$21.00<br \/>\nDescription: They are a fee-based, growth-oriented, traditional master limited partnership initially formed by Hess to own, operate, develop and acquire a diverse set of midstream assets to provide services to Hess and third-party crude oil and natural gas producers.<br \/>\nTrade Date: 4\/6<br \/>\nShares: 12.5 million<br \/>\nUnderwriter(s): Goldman Sachs &amp; Co., Morgan Stanley, Citigroup, J.P. Morgan, MUFG, Wells Fargo Securities<br \/>\nCo Manager(s): ING, Scotia Howard Weil, SMBC Nikko, Barclays, HSBC, TD Securities<br \/>\nTerms Added: 3-27-17<\/p>\n","protected":false},"excerpt":{"rendered":"<p>SUBSCRIBE TO IPOBoutique\u2019s Free Weekly Newsletter\u00a0 The April calendar is beginning to fall into place. After zero IPOs were on the schedule for this current week, our sources indicated that the first week of April would drum up more\u00a0activity. We heard of a few technology companies planning on launching an offering (Okta, Inc. did on[&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24],"tags":[],"class_list":["post-2062","post","type-post","status-publish","format-standard","hentry","category-ipo"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/2062","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=2062"}],"version-history":[{"count":8,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/2062\/revisions"}],"predecessor-version":[{"id":2070,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/2062\/revisions\/2070"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=2062"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=2062"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=2062"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}